Despite maximal medical management, some children
|
|
- Mitchell Fleming
- 6 years ago
- Views:
Transcription
1 Rapid Cardiopulmonary Support for Children With Complex Congenital Heart Disease Jeffrey P. Jacobs, MD, Jorge W. Ojito, BS, CCP, Todd W. McConaghey, CCP, Bryan D. Boden, BS, CCP, Anthony C. Chang, MD, Abdul Aldousany, MD, Evan M. Zahn, MD, and Redmond P. Burke, MD Divisions of Cardiovascular Surgery and Cardiology, Miami Children s Hospital, Miami, and Division of Thoracic and Cardiovascular Surgery, All Children s Hospital, University of South Florida College of Medicine, St. Petersburg, Florida Background. Extracorporeal membrane oxygenation has limitations in children with congenital heart disease (prolonged setup times, increased postoperative blood loss, and difficulty during transport). We developed a miniaturized cardiopulmonary support circuit to address these limitations. Patients and Methods. The cardiopulmonary support system includes a preassembled, completely heparincoated circuit, a BP-50 Bio-Medicus centrifugal pump, a Minimax plus membrane oxygenator, a Bio-Medicus flow probe, and a Bio-trend hematocrit/oxygen saturation monitor. Short tubing length permits a 250-mL bloodless prime in less than 5 minutes. From 1995 to 1997, 23 children with congenital heart disease were supported with this technique. Results. Overall survival to discharge was 48% (11 of 23 patients). Survival to discharge was 80% (4 of 5) in the preoperative support group, 20% (1 of 5) in the postoperative failure to wean from cardiopulmonary bypass group, 44% (4 of 9) in the group placed on support postoperatively after transfer to the intensive care unit, and 50% (2 of 4 patients) in the nonoperative group. Neonatal cardiopulmonary support survival to discharge was 46% (6 of 13 patients). Conclusions. This pediatric cardiopulmonary support system is safe and effective. Advantages over conventional extracorporeal membrane oxygenation include rapid setup time, decreased postoperative blood loss, and simplified transport. (Ann Thorac Surg 2000;70:742 50) 2000 by The Society of Thoracic Surgeons Despite maximal medical management, some children with congenital heart disease will persist with a severe refractory low cardiac output state and require some form of extracorporeal life support. Potential solutions for pediatric patients with poor cardiac function are more limited than for adult cardiac patients. Most current mechanical circulatory support devices were designed for adult patients and are not available or functional for the pediatric population. Extracorporeal membrane oxygenation (ECMO) remains the standard pediatric technique used for extracorporeal life support. Limitations in available therapeutic modalities, combined with the effectiveness and familiarity of ECMO in long-term pulmonary support, have compelled most pediatric centers to use conventional ECMO for cardiac support and emergency resuscitation. Although effective in providing pulmonary support, conventional ECMO may not be the best method of providing complete cardiopulmonary support for children with congenital heart disease and refractory cardiopulmonary dysfunction. In this patient population, ECMO has several limitations including prolonged setup times (45 to 60 minutes), larger priming volumes (450 to Accepted for publication Mar 4, Address reprint requests to Dr Jacobs, Division of Thoracic and Cardiovascular Surgery, All Children s Hospital, 603 Seventh St S, Suite 450, St. Petersburg, FL 33701; jjacobs1@compuserve.com. 800 ml), increased postoperative blood loss, and difficulty during transport. Extracorporeal membrane oxygenation assembly times are often prolonged by numerous factors including debubbling the silicone membrane oxygenator, using CO 2 flushing, and adding blood to the prime. Systemic heparinization can lead to bleeding complications, particularly in the postoperative patient. Patient transport on ECMO is challenging due to nonmobile systems that require gravitational drainage and separate battery packs. In an attempt to address these limitations, we developed a miniaturized cardiopulmonary support (CPS) circuit that can be assembled and primed in less than 5 minutes. Short tubing length permits a 250-mL bloodless prime even in neonates. Complete Carmeda (Carmeda, Medtronic Cardiopulmonary, Anaheim, CA) coating reduces heparin requirements in an effort to reduce postoperative blood loss. The modular system is designed to facilitate patient transport; furthermore, gravity drainage is not necessary with the centrifugal pump. We report our initial experience with this CPS system in 23 children with congenital heart disease and severe cardiopulmonary dysfunction. Material and Methods The CPS system consists of a preassembled, completely heparin-coated (Carmeda) circuit with 0.25-inch arterial 2000 by The Society of Thoracic Surgeons /00/$20.00 Published by Elsevier Science Inc PII S (00)
2 Ann Thorac Surg JACOBS ET AL 2000;70: CPS FOR CONGENITAL HEART DISEASE 743 Fig 1. The cardiopulmonary support system consists of a preassembled Carmeda-coated circuit, a BP-50 Bio-Medicus cone, a Minimax plus oxygenator, a Bio-Medicus flow probe, and Bio-trend hematocrit/oxygen saturation monitor. The centrifugal head and membrane oxygenator are attached both to the patient s bed and the mobile cart by a flexible arm coming off the cart and clamped on the bed. and venous tubing, a BP-50 Bio-Medicus centrifugal pump (Medtronic Bio-Medicus, Eden Prairie, MN), a Minimax plus membrane oxygenator (Medtronic Cardiopulmonary, Anaheim, CA), a Bio-Medicus flow probe (Medtronic Bio-Medicus), and a Bio-trend hematocrit/ oxygen saturation monitor (Medtronic Cardiopulmonary) (Fig 1). In patients weighing more than 30 kg, 3/8-inch arterial and venous tubing, a BP-80 Bio-Medicus cone, and a Maxima plus oxygenator are used. A Bio-Medicus external drive unit and a Minimax oxygenator bracket are attached directly to the patient s bedside where the system can be assembled and primed in less than 5 minutes. The centrifugal head and membrane oxygenator are attached both to the patient s bed and the mobile cart by a flexible arm coming off the cart and clamped on the bed (Fig 1). After assembly, the circuit is primed with a total volume of 250 ml of Plasma-Lyte A solution (Baxter Healthcare Corporation, Deerfield, IL) and quickly debubbled. The arterial and venous lines are in a sterile wrapper and both include tubing spikes for rapid connection to the crystalloid bag. The flow probe transducer and venous saturation monitor are attached and calibrated. The gas line and temperature probe are then attached to the oxygenator. The arterial and venous lines are clamped and transferred to the sterile field. Before cannulation, the preoperative and nonoperative support patients are heparinized using 100 IU/kg (9 of 23 patients). The postoperative group is given 50 IU/kg (7 of 23 patients) or no heparin if actively bleeding (7 of 23 patients). Patients are cannulated by one of three techniques: a midsternotomy with direct right atrial and aortic cannulation (12 of 23 patients), a cervical cut-down with right common carotid artery and right internal jugular vein cannulation (10 of 23 patients), or a groin cut-down with femoral artery and femoral vein cannulation (1 of 23 patients). Patients with open chests and those status post recent sternotomy undergo mediastinal cannulation; otherwise, neck cannulation is used. Femoral cannulation may be considered in larger children; the femoral venous cannula can be advanced superiorly to the right atrium. After cannulation, the arterial and venous lines are connected to the appropriate cannulas. The bypass bridge is clamped, bypass is initiated, and the flow rate slowly increased to 60 to 120 ml kg 1 min 1 depending on patient size and blood flow requirements. Patients with direct mediastinal cannulation also have a left-sided vent placed if left heart decompression is considered necessary. This vent is then connected to the right atrial venous line tubing with a Y connector. Boluses of 5% albumin are administered to maintain the central venous pressure at more than 5 mm Hg to prevent venous line cavitation. Blood products are administered directly to the patient only after achieving full support. None of the patients required blood for priming the CPS circuits. The activated clotting time is measured as soon as possible and maintained between 180 to 220 seconds with a heparin infusion titrated at a minimum of 25 IU kg 1 h 1. Heparin administration is withheld from postoperative patients until bleeding subsides. Seven patients were maintained on CPS without heparin administration until bleeding ceased; the longest period on CPS without heparin administration was 24 hours. Coagulation function is monitored and treated based on thromboelastograph results. In an attempt to prevent circuit thrombus formation, platelets and calcium chloride are administered directly to the patient and not through the CPS circuit. Protamine is avoided at all times. Preoxygenator pressures are continuously monitored with the pressure monitor built into the Bio-Medicus pump console. Systemic-to-pulmonary shunts are partially occluded during support with a bulldog clamp or tourniquet to prevent excess pulmonary blood flow. The degree of shunt occlusion is decreased during the CPS weaning process. Patients From 1995 to 1997, 23 children with congenital heart disease were supported with this technique, representing 2.2% (23 of 1,029) of patients with congenital heart disease treated at Miami Children s Hospital during this time period. A CPS database (a component of the CardioAccess International Clinical Outcomes Database, Cardio- Access Inc, Miami, and St. Petersburg, FL) has been prospectively maintained on all patients and has been used for data collection and analysis. Patient data are summarized in Table 1. Children with congenital heart disease were supported with CPS when they demonstrated a severe refractory low cardiac output state despite maximal medical management including maximal inotropic support. Five patients were supported preoperatively (group 1), 14 patients were supported postoperatively (group 2, representing 1.4% of all surgical cases [14 of 1,007] and
3 744 JACOBS ET AL Ann Thorac Surg CPS FOR CONGENITAL HEART DISEASE 2000;70: Table 1. Patient Characteristics and Outcome Characteristics All CPS Patients Neonates Preoperative Support (Group 1) Postoperative Support (Group 2) Postoperative OR (Group 2a) Postoperative ICU (Group 2b) Nonoperative (Group 3) Number Age Mean (days) 1, , , Median (days) Mode (days) 2 2 Not applicable 7 Not applicable 13 Not applicable Range (days) 2 5, , , , , ,945 Weight Mean (kg) Median (kg) Mode (kg) Not applicable 3.5 Not applicable Range (kg) CPS time per patient Mean (h) Standard error of the mean (h) Range (h) Mean (days) Standard error of the mean (days) Range (days) Total CPS time (h/days) 1,332.76/ / /2.15 1,068.43/ / / /8.9 Successful weaning and decannulation (number [%]) 17/23 [74%] 9/13 [69%] 5/5 [100%] 10/14 [71%] 4/5 [80%] 6/9 [67%] 2/4 [50%] Survival to discharge (number [%]) 11/23 [48%] 6/13 [46%] 4/5 [80%] 5/14 [36%] 1/5 [20%] 4/9 [44%] 2/4 [50%] Late survival (number [%]) 9/23 [39%] 6/13 [46%] 4/5 [80%] 4/14 [29%] 0/5 [0%] 4/9 [44%] 1/4 [25%] CPS cardiopulmonary support; ICU intensive care unit; OR operating room.
4 Ann Thorac Surg JACOBS ET AL 2000;70: CPS FOR CONGENITAL HEART DISEASE 745 Table 2. HLHS Compared to Non-HLHS Variables All CPS Patients HLHS Patients Non-HLHS Patients All Neonates HLHS Neonates Non-HLHS Neonates Number Successful weaning and 17/23 [74%] 4/5 [80%] 13/18 [72%] 9/13 [69%] 4/5 [80%] 5/8 [63%] decannulation (number [%]) Survival to discharge 11/23 [48%] 2/5 [40%] 9/18 [50%] 6/13 [46%] 2/5 [40%] 4/8 [50%] (number [%]) Late survival (number [%]) 9/23 [39%] 2/5 [40%] 7/18 [39%] 6/13 [46%] 2/5 [40%] 4/8 [50%] CPS cardiopulmonary support; HLHS hypoplastic left heart syndrome. 2.7% of all cardiopulmonary bypass cases [14 of 522]), and 4 patients required support but not operation (group 3). The postoperative group includes two subgroups: 5 patients who could not be weaned from cardiopulmonary bypass and were placed on CPS in the operating room (group 2a, representing 0.96% of all cardiopulmonary bypass cases [5 of 522]), and 9 patients placed on CPS after successful weaning from cardiopulmonary bypass and transferred to the intensive care unit (group 2b, representing 1.7% of all cardiopulmonary bypass cases [9 of 522]). Overall median patient age was 22 days (mean, 1,105 days; mode, 2 days; range, 2 to 5,366 days). Overall median patient weight was 3.8 kg (mean, 12.9 kg; mode, 3.5 kg; range, 2.6 to 53 kg). Overall CPS time per patient was hours ( days) (mean standard error of the mean; range, 0.77 to hours or 0.03 to 8.9 days). Total CPS time was 1, hours or days. In group 1, diagnoses included double outlet right ventricle (n 2), critical aortic stenosis (n 1), cardiomyopathy (n 1), and tetralogy of Fallot (n 1). Group 1 median patient age was 29 days (mean, 1,096 days; range, 2 to 5,366 days). Group 1 median patient weight was 4 kg (mean, 12.8 kg; mode, 4 kg; range, 3.2 to 49 kg). Group 1 CPS time per patient was hours ( days) (mean standard error of the mean; range, 0.77 to hours or 0.03 to 1.41 days). Total CPS time in group 1 was hours or 2.15 days. In group 2, diagnoses included hypoplastic left heart syndrome (HLHS) (n 5), aortic stenosis (n 3), total anomalous pulmonary venous drainage (n 2), pulmonary atresia (n 2), tetralogy of Fallot (n 1), and mitral regurgitation (n 1). Group 2 median patient age was 17.5 days (mean, 905 days; mode, 7 days; range, 2 to 4,968 days). Group 2 median patient weight was 3.75 kg (mean, kg; mode, 3.5 kg; range, 3 to 53 kg). Group 2 CPS time per patient was hours ( days) (mean standard error of the mean; range, to hours or 0.74 to 8.9 days). Total CPS time in group 2 was 1, hours or days. In group 2a, diagnoses included HLHS (n 3), aortic stenosis (n 1), and mitral regurgitation (n 1). In group 2b, diagnoses included HLHS (n 2), aortic stenosis (n 2), total anomalous pulmonary venous drainage (n 2), pulmonary atresia (n 2), and tetralogy of Fallot (n 1). In group 3, diagnoses included truncus arteriosus (n 1), previously repaired mitral stenosis with pneumonia (n 1), Wolff-Parkinson-White syndrome (n 1), and tricuspid regurgitation (n 1). Group 3 median patient age was 1,162.5 days (mean, 1,818 days; range, 2 to 4,945 days). Group 3 median patient weight was 4.9 kg (mean, 16.4 kg; range, 2.6 to 53 kg). Group 3 CPS time per patient was hours ( days) (mean standard error of the mean; range, to hours or 1.5 to 3.1 days). Total CPS time in group 3 was hours or 8.9 days. Thirteen neonates required CPS for perioperative support. Diagnoses included HLHS (n 5), total anomalous pulmonary venous drainage (n 2), tricuspid regurgitation (n 1), aortic stenosis (n 1), tetralogy of Fallot (n 1), pulmonary atresia (n 1), double outlet right ventricle (n 1), and truncus arteriosus (n 1). Neonatal median patient age was 9 days (mean, 10.1 days; mode, 2 days; range, 2 to 29 days). Neonatal median patient weight was 3.5 kg (mean, 3.4 kg; mode, 3.5 kg; range, 2.6 to 4.0 kg). Neonatal CPS time per patient was hours ( days) (mean standard error of the mean; range, 0.77 to hours or 0.03 to 7.1 days). Total neonatal CPS time was hours or days. Results Outcome analysis is summarized in Table 1. Outcome analysis is compared for HLHS and non-hlhs patients in Table 2. Successful Cardiopulmonary Support Weaning Overall successful weaning from CPS and decannulation was 74% (17 of 23 patients). Excluding HLHS, successful weaning from CPS and decannulation was 72% (13 of 18 patients). Successful weaning from CPS and decannulation was 80% (4 of 5 patients) in the HLHS patients. Successful weaning from CPS and decannulation was 100% (5 of 5) in the preoperative group (group 1), 80% (4 of 5) in the postoperative failure to wean group (group 2a), 67% (6 of 9) in the postoperative intensive care unit group (group 2b), and 50% (2 of 4 patients) in the nonoperative group (group 3). In 13 neonates requiring CPS, survival to successful weaning from CPS and decannulation was 69% (9 of 13 patients). Excluding HLHS, neonatal CPS survival to
5 746 JACOBS ET AL Ann Thorac Surg CPS FOR CONGENITAL HEART DISEASE 2000;70: successful weaning and decannulation was 63% (5 of 8 patients). Survival to Discharge Overall survival to discharge was 48% (11 of 23 patients). Excluding HLHS, survival to discharge was 50% (9 of 18 patients). Survival was 40% (2 of 5 patients) in the HLHS patients. Survival to discharge was 80% (4 of 5) in the preoperative group (group 1), 20% (1 of 5) in the postoperative failure to wean group (group 2a), 44% (4 of 9) in the postoperative intensive care unit group (group 2b), and 50% (2 of 4 patients) in the nonoperative group (group 3). In 13 neonates requiring CPS, survival to discharge was 46% (6 of 13 patients). Excluding HLHS, neonatal CPS survival to discharge was 50% (4 of 8 patients). Late Survival Two patients died after hospital discharge resulting in an overall late survival rate of 39% (9 of 23 patients). Excluding HLHS, late survival is 39% (7 of 18 patients). Late survival is 40% (2 of 5 patients) in the HLHS patients. Both of these surviving Norwood stage I patients have since gone on to have successful stage 2 bidirectional Glenn procedures. Late survival is 80% (4 of 5) in the preoperative group (group 1), 0% (0 of 5) in the postoperative failure to wean group (group 2a), 44% (4 of 9) in the postoperative intensive care unit group (group 2b), and 25% (1 of 4 patients) in the nonoperative group (group 3). In 13 neonates requiring CPS, late survival is 46% (6 of 13 patients). Excluding HLHS, neonatal CPS late survival is 50% (4 of 8 patients). Blood Transfusion Data Overall total blood product (red blood cells [RBC]) requirements during support averaged ml kg 1 day 1 (mean standard error of the mean; range, 0 to ml kg 1 day 1 ). This RBC requirement equates to ml/m 2 per hour or 4.58 adult units per patient. In group 1, blood product (RBC) requirements during support averaged ml kg 1 day 1 (mean standard error of the mean; range, 0 to 78 ml kg 1 day 1 ). In group 2, blood product (RBC) requirements during support averaged ml kg 1 day 1 (mean standard error of the mean; range, 5.7 to ml kg 1 day 1 ). Cardiopulmonary Resuscitation Time Four patients required cardiopulmonary resuscitation (CPR) before the initiation of CPS. Cardiopulmonary resuscitation time was minutes (mean standard error of the mean; range, 5 to 20 minutes). All of these 4 patients survived to discharge. Comment In children with congenital heart disease, severe low cardiac output may be refractory to maximal medical management. Mechanical circulatory support may allow salvage of many of these critically ill patients. The field of pediatric mechanical circulatory support is evolving rapidly. Several of the current devices that augment or replace cardiac pump function were designed for adult patients and are not applicable to the pediatric population. Three forms of mechanical support are currently available to infants and children: (1) the intraaortic balloon pump, (2) the ventricular assist device (VAD), and (3) ECMO; each technique has advantages and disadvantages. The intraaortic balloon pump provides hemodynamic augmentation, increases diastolic coronary blood flow, and decreases left ventricular afterload. Advantages of the intraaortic balloon pump in adults include its relative ease of insertion and removal as well as the need for limited, if any, anticoagulation. This technique is also the least invasive form of mechanical support. Unfortunately, the intraaortic balloon pump has numerous disadvantages in the pediatric population [1]. Hemodynamic augmentation is often inadequate because of the compliant elastic aortic wall in children [2]. Vascular problems occur with insertion because of the small femoral artery size [3]. The rapid heart rate in many children interferes with timing of the intraaortic balloon [4]. Finally, the balloon has been reported to occasionally occlude the superior mesenteric artery and renal artery as well as cause severe limb ischemia [2]. Consequently, although smaller balloons are currently being developed [5], the application of intraaortic balloon pump is mainly limited to larger children and adults. Three types of VAD may be used: (1) the left VAD (LVAD), (2) the right VAD (RVAD), and (3) the biventricular assist device (BVAD). The LVAD has been shown to be extremely useful in adults with ischemic heart disease and isolated left ventricular dysfunction. Children with left ventricular dysfunction are less likely to have preserved right ventricular function and pulmonary function. Nevertheless, in cases of isolated left ventricular dysfunction, the LVAD has been used with eventual survival of 40% to 70% [6 8]. Similarly, a RVAD can be used for isolated right ventricular dysfunction, which is uncommon in the pediatric population. Finally, a BVAD can be used in cases of biventricular dysfunction, which unfortunately is uncommon without pulmonary dysfunction in small children. Furthermore, BVAD utilization can be technically challenging in smaller children. Advantages of VADs include providing good oxygen delivery to the tissues as well as unloading the supported ventricle to allow time for ventricular healing. Also, the VAD may allow for lower levels of anticoagulation than ECMO. Disadvantages of VAD include bleeding complications, potential pulmonary dysfunction necessitating conversion to ECMO, potential renal dysfunction necessitating hemofiltration, and potential for infection. Furthermore, most VADs also require a median sternotomy for direct access to the heart before cannulation, which restricts their use during acute cardiac failure. Several newer VADs including the implantable TCI Heartmate (Heartmate, Thermo Cardiosystems, Inc,
6 Ann Thorac Surg JACOBS ET AL 2000;70: CPS FOR CONGENITAL HEART DISEASE 747 Woburn, MA) and the paracorporeal Abiomed pump (ABIOMED, Danvers, MA) are being used successfully in adults to replace ventricular function for long periods of time. Unfortunately smaller versions of these systems are not yet available for the pediatric patient. New pediatric VAD systems are now being studied including the Berlin Heart VAD (Berlin Heart, German Heart Institute, Berlin, Germany) [9] and the Jarvik 2000 (Oxford Heart Centre, Oxford, UK, and Texas Heart Institute, Houston, TX) [10]. The MEDOS HIA-VAD System (Helmholtz Institute of Biomedical Technology, Aachen, Germany) is also under development in Europe. This pneumatic paracorporeal VAD has three left ventricular sizes (10, 25, and 60 ml) and 3 right ventricular sizes (9, 22.5, and 54 ml), is pulsatile, and can be operated at up to 180 cycles per minute [11]. The goal of creating a completely implantable VAD has been achieved in adults but remains elusive in children. Extracorporeal membrane oxygenation using venoarterial bypass with a membrane oxygenator remains the standard technique for extracorporeal life support in children, providing both hemodynamic and pulmonary support [12, 13]. Extracorporeal membrane oxygenation systems generally consist of a silicone membrane oxygenator, a bladder, and a roller pump. Extracorporeal membrane oxygenation results have been excellent as treatment for neonatal respiratory failure with survival more than 80% in many groups including neonates with meconium aspiration and those with persistent fetal circulation (persistent pulmonary hypertension of the newborn) [14]. Extracorporeal membrane oxygenation has been used with increased frequency to provide postcardiotomy support for children with severe cardiopulmonary dysfunction after operation for congenital heart disease. Although the Extracorporeal Life Support Organization reports only 44% survival for cardiac ECMO patients [15], survival in some centers now exceeds 50% [16]. Advantages of ECMO include the possibility of providing total cardiopulmonary support and allowing for cardiac and pulmonary healing. Although this may be accomplished with venous drainage from the right atrium and inflow into the aorta, many centers believe it is important to decompress the left side of the heart as well with an additional drainage catheter in the left atrium. Disadvantages of ECMO include prolonged setup times (45 to 60 minutes), increased postoperative blood loss (blood product requirements, multiple reexplorations to control hemorrhage, and potential for infection), and difficulty during transport. During acute cardiac or pulmonary failure, speed is critical and prolonged ECMO setup times are problematic because of numerous factors including debubbling the silicone membrane oxygenator using CO 2 flushing and adding blood to the prime. Extracorporeal membrane oxygenation requires a large priming volume (450 to 800 ml) that results in unnecessary hemodilution and necessitates blood priming of the circuit. Blood products also require the addition of bicarbonate and calcium to reverse the effect of citrate phosphate dextrose; these additives have been implicated in reperfusion injury [17]. Some centers have resorted to maintaining preprimed ECMO circuits for allotted periods of time in an attempt to overcome the problem of prolonged ECMO setup times [18, 19]. Use of these preprimed circuits accepts the added risk of infection should the circuit become contaminated and the added expense of not using the circuit during the allotted time span. Published reports by centers with extensive ECMO experience in cardiac support also report serious drawbacks with conventional ECMO. These centers report survival rates of 38% to 58% [16, 20, 21]. Extended CPR times are a limiting factor in the effectiveness of any rescue during acute cardiac and pulmonary failure. At the Children s Hospital of Pittsburgh, survival was 100% in patients with CPR times less than 15 minutes, whereas survival was 55% in those who underwent CPR for more than 42 minutes [20]. In a series of 11 children with congenital heart disease who underwent cardiac operation and subsequently suffered postoperative cardiac arrest, del Nido and colleagues [22] reported that the mean duration of CPR was 65 9 minutes until ECMO flow was started. They concluded that the success of resuscitation depends largely on the speed and recognition of the arrest event and the establishment of effective respiratory and circulatory support [22]. Four patients in our series required CPR before the initiation of CPS. Cardiopulmonary resuscitation time was minutes (mean standard error of the mean; range, 5 to 20 minutes). All of these 4 patients survived to discharge. Postoperative blood loss while on support is associated with increases in morbidity and mortality. In a series of 68 patients with congenital heart disease requiring ECMO, RBC requirement was ml/m 2 per hour in survivors and ml/m 2 per hour in nonsurvivors [16]. Our patients required ml/m 2 per hour while on CPS. Other published ECMO series document blood loss of 57 ml kg 1 day 1 [16] and 6.2 adult units per patient [20] (compared to our CPS RBC requirement of ml kg 1 day 1 or 4.58 adult units per patient). The heparin-bonded circuit allows for lower activated clotting time levels and may decrease blood requirements. In postoperative patients with excessive bleeding, heparin is withheld until the bleeding subsides; our CPS circuit has been used without heparin seven times for up to 24 hours without problems. Also, this heparin-bonded circuit may allow a decrease in inflammatory mediators, which could potentiate a decreased transfusion requirement. Children with congenital heart disease often require transport to and from remote sites including the catheterization laboratory, intensive care unit, and operating room. Conventional ECMO systems are often not designed to facilitate patient transport as these nonmobile systems require gravitational drainage and separate battery packs. Our CPS system has been designed to facilitate patient transport. Drainage is not gravity dependent and the system is constructed to create ease of patient transport. The system has been structured to even allow patient transport on CPS by helicopter or fixed-wing
7 748 JACOBS ET AL Ann Thorac Surg CPS FOR CONGENITAL HEART DISEASE 2000;70: aircraft and has actually been used for patient transport by helicopter. Adult CPS systems have been used for rapid resuscitation during acute cardiac and pulmonary failure for many years [23 25]. Cardiopulmonary support systems are designed as highly mobile units that offer the highrisk cardiac patient a safety net in the interventional cardiac catheterization laboratory. In the pediatric setting, CPS has not achieved widespread acceptance, in part due to the lower number of pediatric interventional catheterizations being performed. The relatively large priming volume of these systems causes excessive hemodilution and further limits their appeal in the pediatric setting. The volumes of both pediatric interventional catheterization and complete neonatal surgical repair are increasing. The need exists for a rapid and mobile miniature CPS system suitable for neonates. Dalton and colleagues [20] reported that neonates requiring ECMO for congenital heart disease had a 27% survival rate when compared to 42% for older children. Miniaturized versions of the adult CPS systems have previously been described, but these systems still require the addition of blood during priming [26]. We created a modified CPS system to accelerate circuit setup time, reduce the priming volume, eliminate the need for blood priming, reduce transfusion-related risk, prevent the inherent delay required to obtain blood products, decrease postoperative blood loss, and simplify patient transport. Our CPS system permits rapid assembly and bloodless prime. This circuit can be assembled and primed in less than 5 minutes; critically ill patients with closed chests can be placed on support within 15 minutes minimizing end organ injury and preserving ventricular function. Postoperative blood loss and related complications such as multiple reexplorations may be reduced with the Carmeda coating and decreased heparin requirements. The streamlined modular system simplifies patient transport. Patient mobility is also enhanced with an adjustable arm that attaches the cart to the stretcher making the transport safer. Systemic-to-pulmonary shunt management during ECMO or CPS is controversial. We partially occluded these shunts during support with a bulldog clamp or tourniquet to prevent excess pulmonary blood flow. We then gradually decreased the degree of shunt occlusion during the CPS weaning process. Jaggers and colleagues [27] at Duke University have reported successful results leaving the shunt open during the period of ECMO support. In their series, for patients with aortopulmonary shunt, survival was significantly better (4 of 5; 80%) if the aortopulmonary shunt was left open during the period of support (with pump flows increased as necessary to adequately perfuse both the systemic and pulmonary bed) compared to those in whom the shunt was occluded (0 of 4; 0%) (p 0.047). The correct timing for initiation of support is critical but difficult to define. Some studies have shown hospital survival was generally better for those patients in whom support was initiated in the operating room (10 of 15; 67%) versus postoperatively in the intensive care unit (11 of 20; 55%) [27]. In our series, although successful weaning and decannulation was better for those patients in whom support was initiated in the operating room versus postoperatively in the intensive care unit, survival to discharge was better in those in whom support was initiated postoperatively in the intensive care unit compared to in the operating room. The optimal candidate for mechanical circulatory support should be the patient with cardiac or respiratory dysfunction refractory to maximal medical management who falls into at least one of four groups: 1. Patients prior to cardiac surgical repair who have a surgically correctable lesion but cannot be stabilized by conventional means before operation. 2. Patients status post cardiac surgical repair whose cardiac or respiratory dysfunction is not caused by a further surgically correctable lesion and is thought to be reversible with time to allow for cardiac or pulmonary healing while on support. (Patients status post cardiac surgical repair with residual surgically correctable lesions will do poorly unless these lesions are corrected.) 3. Patients not in need of cardiac surgical repair whose cardiac or respiratory dysfunction is thought to be reversible with time to allow for cardiac or pulmonary healing while on support. 4. Patients believed to be reasonable candidates for bridging to transplantation. Our CPS system may prove useful in any of the above settings. Two potential disadvantages with our CPS system exist. The first shortfall is limited oxygenator durability. Hollow fiber oxygenators are not intended for long-term use ( 6 hours) due to plasma breakthrough and loss of oxygenator efficiency [28]. Still, only 4 of our patients required oxygenator and circuit changes during the period of support and the vast majority were supported for several days without circuit failures. The second disadvantage is the increased potential for air embolism secondary to venous line cavitation. Although the centrifugal cone and membrane oxygenator will trap small amounts of air, they are not 100% effective. Because of these potential risks, close continuous circuit monitoring by a perfusionist is necessary. This experience demonstrates that this pediatric CPS system is safe and effective. Advantages over conventional ECMO for children with congenital heart disease and refractory cardiopulmonary dysfunction include rapid setup time, decreased postoperative blood loss, and simplified transport. Further research should lead to more biocompatible support systems as well as smaller support systems. The eventual possibility of developing implantable support systems for long-term system in children is appealing but logistically challenging.
8 Ann Thorac Surg JACOBS ET AL 2000;70: CPS FOR CONGENITAL HEART DISEASE 749 References 1. Gates RN, Cushen CK, Laks H. Cardiopulmonary bypass in infants and children. In: Gravlee GP, Davis RF, Utley JR, eds. Cardiopulmonary bypass Principles and practice, Baltimore: Williams and Wilkins, 1993: Pollock JC, Charlton MC, Williams WG, et al. Intra-aortic balloon pumping in children. Ann Thorac Surg 1980;29: Del Nido PJ, Swan PR, Benson LN, et al. Successful use of intra-aortic balloon pumping in a 2-kilogram infant. Ann Thorac Surg 1988;46: Minich LL, Tani LY, McGough EC, Shaddy RE, Hawkins JA. A novel approach to pediatric intra-aortic balloon pump timing using M-mode echocardiography. Am J Cardiol 1997; 80: Veasy LG, Webster HW, Boucek MM. Pediatric use of intra-aortic balloon pumping. In: Doyle EF, Engle MA, Gersony WM, et al, eds. Pediatric cardiology, New York: Springer-Verlag, 1986: Soto R, Mullaly R, Brizard C, Cochrane A, Horton S, Karl T. Pediatric ventricular assist for low cardiac output: the Melbourne Experience. In:. Proceedings of The Second World Congress of Pediatric Cardiology and Cardiac Surgery, Abstract 484, 1997: Barden C, Lee R. Update on ventricular assist devices [Review]. AACN Clin Issues Crit Care Nurs 1990;1: Rudis E, Drinkwater DC. Circulatory support in infants and children. In: Baue AE, Geha AS, Hammond GL, Laks H, Naunheim, eds. Glenn s thoracic and cardiovascular surgery. Norwalk: Appleton & Lange, 1996: Ishino K, Loebe M, Uhlemann F, Weng Y, Hennig E, Hetzer R. Circulatory support with paracorporeal pneumatic ventricular assist device (VAD) in infants and children. Eur J Cardiothorac Surg 1997;11: Westaby S, Katsumata T, Evans R, Pigott D, Taggart DP, Jarvik RK. The Jarvik 2000 Oxford system: increasing the scope of mechanical circulatory support. J Thorac Cardiovasc Surg 1997;114: Konertz W, Hotz H, Schneider M, Redlin M, Reul H. Clinical experience with the MEDOS HIA-VAD system in infants and children: a preliminary report. Ann Thorac Surg 1997;63: Redmond CR, Graves ED, Falterman KW, Ochner JL, Arensman RM. Extracorporeal membrane oxygenation for respiratory and cardiac failure in infants and children. J Thorac Cardiovasc Surg 1987;93: Galantowicz ME, Stolar CJH. Extracorporeal membrane oxygenation for perioperative support in pediatric heart transplantation. J Thorac Cardiovasc Surg 1991;102: Ichiba S. Current status of extracorporeal membrane oxygenation for severe respiratory failure. Artif Organs 1996;20: Tracy TF, DeLosh T, Bartlett RH. Extracorporeal Life Support organization ASAIO J 1994;40: Walters HL, Hakimi M, Rice MD, Lyons JM, Whittlesey GC, Klein MD. Pediatric cardiac surgical ECMO: multivariate analysis of risk factors for hospital death. Ann Thorac Surg 1995;60: Yano Y, Riggs TR, Milam DF, Alexander JC Jr. Calciumaccentuated ischemic damage during reperfusion J Surg Res 1987;42: Kesser KC, Heard ML, Labuz MD, Pettignano R, Dykes FD. Pre-primed extracorporeal circuit survey. Presented at the Fourteenth Annual Children s National Medical Center Symposium on Extracorporeal Membrane Oxygenation and Advanced Therapies for Respiratory Failure, Keystone, Colorado, March 1998: Young WV, Heemsoth CH, Georgiafandis G, Mitchell DC, Hackett DK, Bahna DG. Extracorporeal circuit sterility after 168 hours. J Extra-corporeal Technol 1997;29: Dalton HJ, Siewers RD, Fuhrman BP, et al. Extracorporeal membrane oxygenation for cardiac rescue in children with severe myocardial dysfunction. Critical Care Med 1993;21: Del Nido P. Extracorporeal membrane oxygenation for cardiac support in children. Ann Thorac Surg 1996;61: Del Nido P. Dalton HJ, Thompson AE, Siewers RD. Extracorporeal membrane oxygenator rescue in children during cardiac arrest after cardiac surgery. Circulation 1992;86:II Hill JG, Bruhn PS, Cohen SE, et al. Emergent applications of cardiopulmonary support: a multiinstitutional experience. Ann Thorac Surg 1993;55: Pavlides GS, Cieszkowski J, Timmis GC, O Neill W. Successful resuscitation of a patient with critical aortic stenosis and cardiac arrest by peripheral cardiopulmonary support system. Cathet Cardiovasc Diagn 1990;20: Phillips SJ, Zeff RH, Kongtahworn C, et al. Percutaneous cardiopulmonary bypass: application and indication for use. Ann Thorac Surg 1989;47: McCoach RM, Myers JL, Wise RK, Baer LD, Williams SA, Williams DR. Use of emergency cardiopulmonary support in neonates and infants. Proc Am Acad Card Perf 1994;15: Jaggers J, Forbess J, Meliones J, Kirshborn PM, Miller C, Ungerleider RM. Extracorporeal membrane oxygenation (ECMO) for post cardiotomy failure in children: significance of shunt management in the single ventricle. Ann Thorac Surg 2000;69: Tamari Y, Tortolani AJ, Lee-Sensiba KJ. Bloodless testing for microporous membrane oxygenator failure: a preliminary study. Intern J Artif Org 1991;14: INVITED COMMENTARY Operative results in children undergoing repair of congenital heart defects has steadily improved over the last two decades. These advances have been due in large part, to improved methods of diagnosis, optimizing timing of surgery, improved myocardial protection and cardiopulmonary bypass, as well as increased experience by the surgical teams. With the improvement in outcome, indications for mechanical circulatory assistance in children have changed. Inability to wean off bypass following repair has become less frequent. However, more centers have recognized the potential benefit of having a rapid response system available for establishing mechanical circulatory assistance in patients who deteriorate early after surgery, sometimes unexpectedly, and also for patients with cardiomyopathy who may deteriorate due to arrhythmias. Whereas traditionally the type of extracorporeal membrane oxygenator circuit that was developed for neonatal respiratory failure has also been utilized for patients with primary cardiac failure, most centers have recognized that important limitations of these types of circuits are the large priming volume and long set up time. Since true ventricular assist devices designed for chronic support of children are currently not available in 2000 by The Society of Thoracic Surgeons /00/$20.00 Published by Elsevier Science Inc PII S (00)
9 750 JACOBS ET AL Ann Thorac Surg CPS FOR CONGENITAL HEART DISEASE 2000;70: the United States, conventional pumps such as the roller head or centrifugal pumps continue to be the only devices available for pediatric use. The need for a mechanism to prevent cavitation from an occluding roller pump has resulted in continued use of gravity dependent drainage, pressure sensitive bladder box as a regulator of electrical power to the roller pump. The limitations of gravity dependent drainage is overcome by an active suction system provided by the centrifugal pump at the expense of durability and a higher potential for cavitation. In the report by Jacobs and colleagues, they describe a system that utilizes a centrifugal pump combined with a hollow fiber oxygenator, which dramatically decreases set up time and minimizes priming volume. This type of system addresses two of the major drawbacks of conventional extracorporeal membrane oxygenator circuits that utilize Teflon membrane oxygenators and roller pumps. The larger priming volume required by this circuit results in increased hemodilution if blood is not available for priming. The long set up time significantly delays initiation of support if a system is not set up and ready to go as is currently done in many cardiac intensive care units. This miniaturized system represents a clear advantage for the rapid institution of mechanical support. It s long term use however is still limited in that durability of the centrifugal pump head as well as efficiency of the hollow fiber oxygenator necessitate conversion to a conventional oxygenator and/or frequent replacement of the circuit if support is required for several days. Use of anticoagulation is still generally recommended even when heparin coated circuits are used since we and others have seen thrombus formation within 24 to 48 hours after initiation of support when heparin levels are kept very low. Alternative strategies for managing postoperative bleeding in cases where mechanical circulatory support is initiated early after surgery are platelet transfusions, administration of cryoprecipitate and fresh frozen plasma to maintain fibrinogen levels, and judicious use of anti-fibrinolytics. In our experience, this approach has resulted in adequate control of operative site bleeding while still administering heparin and minimizing the risk of thromboemboli. Pedro J. del Nido, MD Department of Cardiac Surgery Children s Hospital 300 Longwood Ave, Bader 279 Boston, MA delnido@cardio.tch.harvard.edu.
Understanding the Pediatric Ventricular Assist Device
Understanding the Pediatric Ventricular Assist Device W. James Parks, MSc., MD Pediatric Cardiologist Assistant Professor of Pediatrics and Radiology Children s Healthcare of Atlanta Sibley Heart Center
More informationMechanical Ventricular Circulatory Support in Children; Bad Oeynhausen Experience
Original Article Mechanical Ventricular Circulatory Support in Children; Bad Oeynhausen Experience Kazutomo Minami, MD, PhD, 1 Edzard von Knyphausen, MD, 2 Ryusuke Suzuki, MD, 1 Ute Blanz, MD, 1 Latif
More informationECMO as a bridge to durable LVAD therapy. Jonathan Haft, MD Department of Cardiac Surgery University of Michigan
ECMO as a bridge to durable LVAD therapy Jonathan Haft, MD Department of Cardiac Surgery University of Michigan Systolic Heart Failure Prevalence 4.8 million U.S. 287,000 deaths per year $39 billion spent
More informationImplantable Ventricular Assist Devices and Total Artificial Hearts. Policy Specific Section: June 13, 1997 March 29, 2013
Medical Policy Implantable Ventricular Assist Devices and Total Artificial Hearts Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Surgery Original Policy Date: Effective
More informationWhy Children Are Not Small Adults? Treatment of Pediatric Patients Needing Mechanical Circulatory Support
Why Children Are Not Small Adults? Treatment of Pediatric Patients Needing Mechanical Circulatory Support Utpal S Bhalala, MD, FAAP Assistant Professor and Director of Research Pediatric Critical Care
More informationECMO Primer A View to the Future
ECMO Primer A View to the Future Todd J. Kilbaugh Assistant Professor of Anesthesiology, Critical Care Medicine, and Pediatrics Director of The ECMO Center at the Children s Hospital of Philadelphia Disclosures
More informationCongenital heart operations place extreme demands
Assisted Venous Drainage Cardiopulmonary Bypass in Congenital Heart Surgery Jorge W. Ojito, CCP, Robert L. Hannan, MD, Kagami Miyaji, MD, Jeffrey A. White, MS, Todd W. McConaghey, CCP, Jeffrey P. Jacobs,
More informationTo ECMO Or Not To ECMO Challenges of venous arterial ECMO. Dr Emily Granger St Vincent s Hospital Darlinghurst NSW
To ECMO Or Not To ECMO Challenges of venous arterial ECMO Dr Emily Granger St Vincent s Hospital Darlinghurst NSW The Start: 1972 St Vincent s Hospital The Turning Point ECMO program restarted in 2004
More informationExtracorporeal Membrane Oxygenation in Children After Repair of Congenital Cardiac Lesions
Extracorporeal Membrane Oxygenation in Children After Repair of Congenital Cardiac Lesions Alon S. Aharon, MD, Davis C. Drinkwater, Jr, MD, Kevin B. Churchwell, MD, Susannah V. Quisling, BS, V. Seenu Reddy,
More informationEcho assessment of patients with an ECMO device
Echo assessment of patients with an ECMO device Evangelos Leontiadis Cardiologist 1st Cardiology Dept. Onassis Cardiac Surgery Center Athens, Greece Gibbon HLM 1953 Goldstein DJ et al, NEJM 1998; 339:1522
More informationTHE USE of VENTRICULAR ASSIST DEVICES in CHILDREN: CURRENT OPTIONS & FUTURE TRENDS
THE USE of VENTRICULAR ASSIST DEVICES in CHILDREN: CURRENT OPTIONS & FUTURE TRENDS ADULTS : VAD Better Accepted Technically easier Fewer anatomical constraints HTx is realistic possibility Overall experience
More informationExtra Corporeal Life Support for Acute Heart failure
Extra Corporeal Life Support for Acute Heart failure Benjamin Medalion, MD Director Heart and Lung Transplantation Department of Cardiothoracic Surgery Rabin Medical Center, Beilinson Campus, Israel Mechanical
More informationCase Report. Stent Placement in a Neonate with Sano Modification of the Norwood using Semi-Elective Extracorporeal Membrane Oxygenation.
Stent Placement in a Neonate with Sano Modification of the Norwood using Semi-Elective Extracorporeal Membrane Oxygenation Mustafa Gulgun and Michael Slack Associated Profesor Children National Medical
More informationInnovative ECMO Configurations in Adults
Innovative ECMO Configurations in Adults Practice at a Single Center with Platinum Level ELSO Award for Excellence in Life Support Monika Tukacs, BSN, RN, CCRN Columbia University Irving Medical Center,
More informationECMO CPR. Ravi R. Thiagarajan MBBS, MPH. Cardiac Intensive Care Unit
ECMO CPR Ravi R. Thiagarajan MBBS, MPH Staff Intensivist Cardiac Intensive Care Unit Children s Hospital Boston PCICS 2008, Miami, FL No disclosures Disclosures Outline Outcomes for Pediatric in-hospital
More informationManagement of Cardiogenic Shock. Dr Stephen Pettit, Consultant Cardiologist
Dr Stephen Pettit, Consultant Cardiologist Cardiogenic shock Management of Cardiogenic Shock Outline Definition, INTERMACS classification Medical management of cardiogenic shock PA catheters and haemodynamic
More informationPediatric Mechanical Circulatory Support (MCS)
Pediatric Mechanical Circulatory Support (MCS) Ivan Wilmot, MD Heart Failure, Transplant, MCS Assistant Professor The Heart Institute Cincinnati Children s Hospital Medical Center The University of Cincinnati
More informationMechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know!
Mechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know! Matthew A. Wanat, PharmD, BCPS, BCCCP, FCCM Clinical Assistant Professor University of Houston College of Pharmacy Clinical Pharmacy
More informationAdult Extracorporeal Life Support (ECLS)
Adult Extracorporeal Life Support (ECLS) Steven Scott, M.D., F.A.C.S. Piedmont Heart Institute Cardiothoracic Surgery Disclosures None ECMO = ECLS A technique of life support that involves a continuous
More informationIntroduction. Study Design. Background. Operative Procedure-I
Risk Factors for Mortality After the Norwood Procedure Using Right Ventricle to Pulmonary Artery Shunt Ann Thorac Surg 2009;87:178 86 86 Addressor: R1 胡祐寧 2009/3/4 AM7:30 SICU 討論室 Introduction Hypoplastic
More informationUniversity of Florida Department of Surgery. CardioThoracic Surgery VA Learning Objectives
University of Florida Department of Surgery CardioThoracic Surgery VA Learning Objectives This service performs coronary revascularization, valve replacement and lung cancer resections. There are 2 faculty
More informationUSE OF RAPID-DEPLOYMENT EXTRACORPOREAL MEMBRANE OXYGENATION FOR THE RESUSCITATION OF PEDIATRIC PATIENTS WITH HEART DISEASE AFTER CARDIAC ARREST
USE OF RAPID-DEPLOYMENT EXTRACORPOREAL MEMBRANE OXYGENATION FOR THE RESUSCITATION OF PEDIATRIC PATIENTS WITH HEART DISEASE AFTER CARDIAC ARREST Brian W. Duncan, MD a Andra E. Ibrahim, MD b Viktor Hraska,
More informationAirway Management in a Patient with Klippel-Feil Syndrome Using Extracorporeal Membrane Oxygenator
Airway Management in a Patient with Klippel-Feil Syndrome Using Extracorporeal Membrane Oxygenator Beckerman Z*, Cohen O, Adler Z, Segal D, Mishali D and Bolotin G Department of Cardiac Surgery, Rambam
More informationECMO vs. CPB for Intraoperative Support: How do you Choose?
ECMO vs. CPB for Intraoperative Support: How do you Choose? Shaf Keshavjee MD MSc FRCSC FACS Director, Toronto Lung Transplant Program Surgeon-in-Chief, University Health Network James Wallace McCutcheon
More informationAcute heart failure: ECMO Cardiology & Vascular Medicine 2012
Acute heart failure: ECMO Cardiology & Vascular Medicine 2012 Lucia Jewbali cardiologist-intensivist 14 beds/8 ICU beds Acute coronary syndromes Heart failure/ Cardiogenic shock Post cardiotomy Heart
More informationCardiac anaesthesia. Simon May
Cardiac anaesthesia Simon May Contents Cardiac: Principles of peri-operative management for cardiac surgery Cardiopulmonary bypass, cardioplegia and off pump cardiac surgery Cardiac disease and its implications
More informationRepair or Replacement
Surgical intervention post MitraClip Device: Repair or Replacement Saudi Heart Association, February 21-24 Rüdiger Lange, MD, PhD Nicolo Piazza, MD, FRCPC, FESC German Heart Center, Munich, Germany Division
More informationCase scenario V AV ECMO. Dr Pranay Oza
Case scenario V AV ECMO Dr Pranay Oza Case Summary 53 y/m, k/c/o MVP with myxomatous mitral valve with severe Mitral regurgitation underwent Mitral valve replacement with mini thoracotomy Pump time nearly
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Ablation, radiofrequency, anesthetic considerations for, 479 489 Acute aortic syndrome, thoracic endovascular repair of, 457 462 aortic
More informationMECHANICAL CIRCULATORY SUPPORT IN CHILDREN WITH CARDIAC DISEASE
MECHANICAL CIRCULATORY SUPPORT IN CHILDREN WITH CARDIAC DISEASE Brian W. Duncan, MD a Viktor Hraska, MD a Richard A. Jonas, MD a David L. Wessel, MD b Pedro J. Del Nido, MD a Peter C. Laussen, MD b John
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Cardiogenic Shock Mechanical Support Eulàlia Roig FESC Heart Failure and HT Unit Hospital Sant Pau - UAB Barcelona. Spain No conflics of interest Mechanical Circulatory
More informationAllinaHealthSystem 1
: Definition End-organ hypoperfusion secondary to cardiac failure Venoarterial ECMO: Patient Selection Michael A. Samara, MD FACC Advanced Heart Failure, Cardiac Transplant & Mechanical Circulatory Support
More informationMechanics of Cath Lab Support Devices
Mechanics of Cath Lab Support Devices Issam D. Moussa, MD Chief Medical Officer First Coast Cardiovascular Institute, Jacksonville, FL Professor of Medicine, UCF, Orlando, FL None DISCLOSURE Percutaneous
More informationChildren with Single Ventricle Physiology: The Possibilities
Children with Single Ventricle Physiology: The Possibilities William I. Douglas, M.D. Pediatric Cardiovascular Surgery Children s Memorial Hermann Hospital The University of Texas Health Science Center
More informationMechanical Cardiac Support in Acute Heart Failure. Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research
Mechanical Cardiac Support in Acute Heart Failure Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research Disclosures Research Support and/or Consulting NHLBI Amgen Cytokinetics
More informationInitial experience with Imacor htee-guided management of patients following transplant and mechanical circulatory support.
Thomas Jefferson University Jefferson Digital Commons Department of Cancer Biology Faculty Papers Department of Cancer Biology Fall 11-1-2012 Initial experience with Imacor htee-guided management of patients
More informationIntra-operative Effects of Cardiac Surgery Influence on Post-operative care. Richard A Perryman
Intra-operative Effects of Cardiac Surgery Influence on Post-operative care Richard A Perryman Intra-operative Effects of Cardiac Surgery Cardiopulmonary Bypass Hypothermia Cannulation events Myocardial
More informationAssociated clinical guidelines/protocols: Comprehensive GOSH ECMO guidelines are available in the ECMO office.
Disclaimer: The Great Ormond Street Paediatric Intensive Care Training Programme was developed in 2004 by the clinicians of that Institution, primarily for use within Great Ormond Street Hospital and the
More informationTransfusion and Blood Conservation
Transfusion and Blood Conservation Kenneth G. Shann, CCP Assistant Director, Perfusion Services Senior Advisor, Performance Improvement Department of Cardiovascular and Thoracic Surgery Montefiore Medical
More informationECMO and VAD implantation
1 Udine ECMO Workshop ECMO and VAD implantation Prof. Tomaso Bottio Division of Cardiac Surgery (Director Prof. Gino gerosa) ECMO Extracorporeal membrane oxygena1on (ECMO) is a rescue therapy to support
More informationManagement of a Patient after the Bidirectional Glenn
Management of a Patient after the Bidirectional Glenn Melissa B. Jones MSN, APRN, CPNP-AC CICU Nurse Practitioner Children s National Health System Washington, DC No Disclosures Objectives qbriefly describe
More informationMechanical Support in the Failing Fontan-Kreutzer
Mechanical Support in the Failing Fontan-Kreutzer Stephanie Fuller MD, MS Thomas L. Spray Endowed Chair in Congenital Heart Surgery Associate Professor, The Perelman School of Medicine at the University
More informationSection 6 Intra Aortic Balloon Pump
Section 6 Intra Aortic Balloon Pump The Intra Aortic Balloon Pump (IABP) The balloon is synthetic and is made for single use only. It is threaded into the aorta, usually via a femoral approach. The balloon
More informationJennifer A. Brown The Cleveland Clinic School of Perfusion Cleveland, Ohio
Biventricular Heart Failure Advanced Treatment Options at The Cleveland Clinic Jennifer A. Brown The Cleveland Clinic School of Perfusion Cleveland, Ohio I have no disclosures. Examine respiratory and
More informationORIGINAL ARTICLE. Alexander M. Bernhardt a, *, Theo M.M.H. De By b, Hermann Reichenspurner a and Tobias Deuse a. Abstract INTRODUCTION
European Journal of Cardio-Thoracic Surgery 48 (2015) 158 162 doi:10.1093/ejcts/ezu406 Advance Access publication 29 October 2014 ORIGINAL ARTICLE Cite this article as: Bernhardt AM, De By TMMH, Reichenspurner
More informationMechanics of Cath Lab Support Devices
Mechanics of Cath Lab Support Devices Issam D. Moussa, MD Professor of Medicine Mayo Clinic College of Medicine Chair, Division of Cardiovascular Diseases Mayo Clinic Jacksonville, Florida DISCLOSURE Presenter:
More informationFOCUS CONFERENCE 2018
FOCUS CONFERENCE 2018 Current Practice in Pediatric and Neonatal Extracorporeal Life Support Daniel W. Chipman, RRT Assistant Director of Respiratory Care Massachusetts General Hospital Boston, Massachusetts
More informationExtracorporeal Membrane Oxygenation for Infant Postcardiotomy Support: Significance of Shunt Management
Extracorporeal Membrane Oxygenation for Infant Postcardiotomy Support: Significance of Shunt Management James J. Jaggers, MD, Joseph M. Forbess, MD, Ashish S. Shah, MD, Jon N. Meliones, MD, Paul M. Kirshbom,
More information12/19/2017. Learning Objectives. Mechanical Circulatory Support. Mechanical Aids to External Massage. Noninvasive Mechanical Support Devices
Learning Objectives Mechanical Circulatory Support Explain the indications, function, & complications for selected mechanical circulatory support devices Describe examples of ventricular assist devices
More informationCite this article as:
doi: 10.21037/acs.2018.08.06 Cite this article as: Loforte A, Baiocchi M, Gliozzi G, Coppola G, Di Bartolomeo R, Lorusso R. Percutaneous pulmonary artery venting via jugular vein while on peripheral extracorporeal
More informationBridging With Percutaneous Devices: Tandem Heart and Impella
Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED HEART FAILURE, TX AND MCS SENTARA HEART HOSPITAL NORFOLK, VA PROFESSOR OF MEDICINE
More informationUnderstanding the Cardiopulmonary Bypass Machine and Its Tubing
Understanding the Cardiopulmonary Bypass Machine and Its Tubing Robert S. Leckie, MD Division of Cardiac Anesthesia, Beth Israel Deaconess Medical Center ABL 1/09 Reservoir Bucket This is a cartoon of
More informationLeft Ventricular Assist Devices (LVADs): Overview and Future Directions
Left Ventricular Assist Devices (LVADs): Overview and Future Directions FATIMA KARAKI, M.D. PGY-3, DEPARTMENT OF MEDICINE WASHINGTON UNIVERSITY IN ST. LOUIS ST. LOUIS, MISSOURI, USA St. Louis, Missouri,
More informationFrom Recovery to Transplant: One Patient's Journey
From Recovery to Transplant: One Patient's Journey Tonya Elliott, RN, MSN Assist Device and Thoracic Transplant Coordinator Inova Transplant Center at Inova Fairfax Hospital Falls Church, VA Introduction
More informationECMO as a Bridge to Heart Transplant in the Era of LVAD s.
Christian Bermudez MD. Associate Professor Director Thoracic Transplantation Division Cardiac Surgery Department of Surgery University of Pennsylvania ECMO as a Bridge to Heart Transplant in the Era of
More informationECLS as Bridge to Transplant
ECLS as Bridge to Transplant Marcelo Cypel MD, MSc Assistant Professor of Surgery Division of Thoracic Surgery Toronto General Hospital University of Toronto Application of ECLS Bridge to lung recovery
More informationCardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition
Cardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition Table of Contents Volume 1 Chapter 1: Cardiovascular Anatomy and Physiology Basic Cardiac
More informationCath Lab Essentials : LV Assist Devices for Hemodynamic Support (IABP, Impella, Tandem Heart, ECMO)
Cath Lab Essentials : LV Assist Devices for Hemodynamic Support (IABP, Impella, Tandem Heart, ECMO) Michael A. Gibson, MD Assistant Professor of Medicine University of California, Irvine Division of Cardiology
More informationMechanical circulatory support using ventricular assist
Evaluation of a Pulsatile Pediatric Ventricular Assist Device in an Acute Right Heart Failure Model Dominique Shum-Tim, MD, Brian W. Duncan, MD, Victor Hraska, MD, Ingeborg Friehs, MD, Toshiharu Shin oka,
More informationCounterpulsation. John N. Nanas, MD, PhD. Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece
John N. Nanas, MD, PhD Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece History of counterpulsation 1952 Augmentation of CBF Adrian and Arthur Kantrowitz, Surgery 1952;14:678-87
More informationObjective 2/9/2012. Blood Gas Analysis In The Univentricular Patient: The Need For A Different Perspective. VENOARTERIAL CO2 GRADIENT
Blood Gas Analysis In The Univentricular Patient: The Need For A Different Perspective. Gary Grist RN CCP Chief Perfusionist The Children s Mercy Hospitals and Clinics Kansas City, Mo. Objective The participant
More informationExtracorporeal life support (ECLS) supplements the
CARDIOPULMONARY SUPPORT AND PHYSIOLOGY A PROSPECTIVE COMPARISON OF ATRIO-FEMORAL AND FEMORO-ATRIAL FLOW IN ADULT VENOVENOUS EXTRACORPOREAL LIFE SUPPORT Preston B. Rich, MD Samir S. Awad, MD Stefania Crotti,
More informationChapter 13 Worksheet Code It
Class: Date: Chapter 13 Worksheet 3 2 1 Code It True/False Indicate whether the statement is true or false. 1. A cardiac catheterization diverts blood from the heart to the aorta. 2. Selective vascular
More informationISPUB.COM. Concepts Of Neonatal ECMO. D Thakar, A Sinha, O Wenker HISTORY PATIENT SELECTION AND ECMO CRITERIA
ISPUB.COM The Internet Journal of Emergency and Intensive Care Medicine Volume 5 Number 2 D Thakar, A Sinha, O Wenker Citation D Thakar, A Sinha, O Wenker.. The Internet Journal of Emergency and Intensive
More informationA Unique Milieu for Perioperative Care of Adult Congenital Heart Disease Patients at a Single Institution
Original Article A Unique Milieu for Perioperative Care of Adult Congenital Heart Disease Patients at a Single Institution Ghassan Baslaim, MD, and Jill Bashore, RN Purpose: Adult patients with congenital
More informationMechanical Bleeding Complications During Heart Surgery
Mechanical Bleeding Complications During Heart Surgery Arthur C. Beall, Jr., M.D., Kenneth L. Mattox, M.D., Mary Martin, R.N., C.C.P., Bonnie Cromack, C.C.P., and Gary Cornelius, C.C.P. * Potential for
More informationPerioperative Management of DORV Case
Perioperative Management of DORV Case James P. Spaeth, MD Department of Anesthesia Cincinnati Children s Hospital Medical Center University of Cincinnati Objectives: 1. Discuss considerations regarding
More informationECLS. The Basics. Jeannine Hermens Intensive Care Center UMC Utrecht
ECLS The Basics Jeannine Hermens Intensive Care Center UMC Utrecht Conflict of interest None Terminology ECMO - ExtraCorporeal Membrane Oxygenation ECLS - ExtraCorporeal Life Support PLS - Veno-venous
More informationDEMYSTIFYING VADs. Nicolle Choquette RN MN Athabasca University
DEMYSTIFYING VADs Nicolle Choquette RN MN Athabasca University Objectives odefine o Heart Failure o VAD o o o o Post Operative Complications Acute Long Term Nursing Interventions What is Heart Failure?
More informationMechanical circulatory support is now commonly
Long-Term Survival After Pediatric Cardiac Transplantation and Postoperative ECMO Support Kathleen N. Fenton, MD, Steven A. Webber, MD, David A. Danford, MD, Sanjiv K. Gandhi, MD, Jayson Periera, MD, and
More information3/14/2011 MANAGEMENT OF NEWBORNS CARDIAC INTENSIVE CARE CONFERENCE FOR HEALTH PROFESSIONALS IRVINE, CA. MARCH 7, 2011 WITH HEART DEFECTS
CONFERENCE FOR HEALTH PROFESSIONALS IRVINE, CA. MARCH 7, 2011 MANAGEMENT OF NEWBORNS WITH HEART DEFECTS A NTHONY C. CHANG, MD, MBA, MPH M E D I C AL D I RE C T OR, HEART I N S T I T U T E C H I LDRE N
More information10/10/2018. Disclosures. Introduction (II) Introduction (I) The authors have no disclosures
PERFUSION METHODS AND MODIFICATIONS TO THE CARDIOPULMONARY BYPASS CIRCUIT FOR MIDLINE UNIFOCALIZATION PROCEDURES Tristan D. Margetson CCP, FPP, Justin Sleasman, CCP, FPP, Sami Kollmann, CCP, Patrick J.
More informationA have dovetailed with the availability of a plethora of
Circulatory Support With a Centrifugal Pump Bridge to Cardiac Transplantation R. Morton Bolman 111, MD, James L. Cox, MD, William Marshall, MD, Nicholas Kouchoukos, MD, Thomas L. Spray, MD, Connie Cance,
More informationEvaluation of Native Left Ventricular Function During Mechanical Circulatory Support.: Theoretical Basis and Clinical Limitations
Review Evaluation of Native Left Ventricular Function During Mechanical Circulatory Support.: Theoretical Basis and Clinical Limitations Tohru Sakamoto, MD, PhD Left ventricular function on patients with
More informationRight Ventricular Failure: Prediction, Prevention and Treatment
Right Ventricular Failure: Prediction, Prevention and Treatment 3 rd European Training Symposium for Heart Failure Cardiologists and Cardiac Surgeons University Hospital Bern June 24-25, 2016 Disclosures:
More informationCASE PRESENTATION Ravi Dhanisetty, M.D. SUNY Downstate 23 July 2009 CASE PRESENTATION xx yr old female with chest pain for 3 days. Initially taken to outside hospital 3 days history of chest pain, shortness
More informationHemodynamic Monitoring and Circulatory Assist Devices
Hemodynamic Monitoring and Circulatory Assist Devices Speaker: Jana Ogden Learning Unit 2: Hemodynamic Monitoring and Circulatory Assist Devices Hemodynamic monitoring refers to the measurement of pressure,
More informationLV Distension and ECLS Lungs
LV Distension and ECLS Lungs Kevin W. Hatton, MD, FCCM Interim Vice-Chair for Anesthesiology Research Division Chief, Anesthesiology Critical Care Medicine Program Director, Anesthesiology Critical Care
More informationCirculatory Support: From IABP to LVAD
Circulatory Support: From IABP to LVAD Howard A Cohen, MD, FACC, FSCAI Director Division of Cardiovascular Intervention Co Director Cardiovascular Interventional ti Laboratories Lenox Hill Heart & Vascular
More informationCurricular Components for Cardiology EPA
Curricular Components for Cardiology EPA 1. EPA Title 2. Description of the Activity Diagnosis and management of patients with acute congenital or acquired cardiac problems requiring intensive care. Upon
More informationThe Role of Mechanical Circulatory Support in Cardiogenic Shock: When to Utilize
The Role of Mechanical Circulatory Support in Cardiogenic Shock: Presented by Nancy Scroggins ACNP, CNS-CC CV Surgery ACNP Bayshore Medical Center The Role of Mechanical Circulatory Support in Cardiogenic
More informationManagement of Acute Shock and Right Ventricular Failure
Management of Acute Shock and Right Ventricular Failure Nader Moazami, MD Department of Thoracic and Cardiovascular Surgery and Biomedical Engineering, Cleveland Clinic NONE Disclosures CARDIOGENIC SHOCK
More informationCARDIOVASCULAR SURGERY
Volume 107, Number 4 April 1994 The Journal of THORACIC AND CARDIOVASCULAR SURGERY Cardiac and Pulmonary Transplantation Risk factors for graft failure associated with pulmonary hypertension after pediatric
More informationComparison of Flow Differences amoiig Venous Cannulas
Comparison of Flow Differences amoiig Venous Cannulas Edward V. Bennett, Jr., MD., John G. Fewel, M.S., Jose Ybarra, B.S., Frederick L. Grover, M.D., and J. Kent Trinkle, M.D. ABSTRACT The efficiency of
More informationDiversion of the inferior vena cava following repair of atrial septal defect causing hypoxemia
Marshall University Marshall Digital Scholar Internal Medicine Faculty Research Spring 5-2004 Diversion of the inferior vena cava following repair of atrial septal defect causing hypoxemia Ellen A. Thompson
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Acute coronary syndrome(s), anticoagulant therapy in, 706, 707 antiplatelet therapy in, 702 ß-blockers in, 703 cardiac biomarkers in,
More informationA Validated Practical Risk Score to Predict the Need for RVAD after Continuous-flow LVAD
A Validated Practical Risk Score to Predict the Need for RVAD after Continuous-flow LVAD SK Singh MD MSc, DK Pujara MBBS, J Anand MD, WE Cohn MD, OH Frazier MD, HR Mallidi MD Division of Transplant & Assist
More informationClinical Applications of Femoral Vein-to-Artery Cannulation for Mechanical Cardiopulmonary Support and Bypass
Clinical Applications of Femoral Vein-to-Artery Cannulation for Mechanical Cardiopulmonary Support and Bypass Robert L. Berger, M.D., Virender K. Saini, M.D., and Everett L. Dargan, M.D. ABSTRACT Femoral
More informationMechanical Circulatory Support: Reality and Dreams Experience of a Single Center
The Journal of The American Society of Extra-Corporeal Technology Mechanical Circulatory Support: Reality and Dreams Experience of a Single Center H.-H. Weitkemper, RN, ECCP; A. El-Banayosy, MD; L. Arusoglu,
More informationHeart Transplantation in Patients with Superior Vena Cava to Pulmonary Artery Anastomosis: A Single-Institution Experience
Korean J Thorac Cardiovasc Surg 2018;51:167-171 ISSN: 2233-601X (Print) ISSN: 2093-6516 (Online) CLINICAL RESEARCH https://doi.org/10.5090/kjtcs.2018.51.3.167 Heart Transplantation in Patients with Superior
More informationUseful? Definition of High-risk? Pre-OP/Intra-OP/Post-OP? Complication vs Benefit? Mortality? Morbidity?
Preoperative intraaortic balloon counterpulsation in high-risk CABG Stefan Klotz, M.D. Preoperative IABP in high-risk CABG Questions?? Useful? Definition of High-risk? Pre-OP/Intra-OP/Post-OP? Complication
More informationComplications of Acute Myocardial Infarction
Acute Myocardial Infarction Complications of Acute Myocardial Infarction Diagnosis and Treatment JMAJ 45(4): 149 154, 2002 Hiroshi NONOGI Director, Division of Cardiology and Emergency Medicine, National
More informationPercutaneous Mechanical Circulatory Support Devices
Percutaneous Mechanical Circulatory Support Devices Daniel Vazquez RN, RCIS Miami Cardiac & Vascular Institute FINANCIAL DISCLOSURES none CASE STUDY CASE STUDY 52 year old gentlemen Complaining of dyspnea
More informationAPPROACH TO THE ICCU PATIENT WITH PULMONARY HYPERTENSION
APPROACH TO THE ICCU PATIENT WITH PULMONARY HYPERTENSION Rafael Hirsch, Adult Congenital Heart Unit Dept. of Cardiology Rabin Medical Center Beilinson Campus & Tel Aviv University Sackler School of Medicine,
More informationAugust, 2015 STATE MEDICAL FACULTY OF WEST BENGAL. Preliminary Examinations for Diploma in Perfusion Technology : DPfT. Paper I ANATOMY & PHYSIOLOGY
August, 2015 STATE MEDICAL FACULTY OF WEST BENGAL Paper I ANATOMY & PHYSIOLOGY Time 3 hours Full Marks 80 Group A Q-1) Write the correct Answer: 10x1 = 10 i) The posterior descending artery is branch of
More informationHemodynamic Monitoring
Perform Procedure And Interpret Results Hemodynamic Monitoring Tracheal Tube Cuff Pressure Dean R. Hess PhD RRT FAARC Hemodynamic Monitoring Cardiac Rate and Rhythm Arterial Blood Pressure Central Venous
More informationECMO BASICS CHLOE STEINSHOUER, MD PULMONARY AND SLEEP CONSULTANTS OF KANSAS
ECMO BASICS CHLOE STEINSHOUER, MD PULMONARY AND SLEEP CONSULTANTS OF KANSAS DISCLOSURES No financial disclosures or conflicts of interest OBJECTIVES Define ECMO/ECLS and be able to identify the main types
More informationPlanned, Short-Term RVAD During Durable LVAD Implant: Indications and Management
Planned, Short-Term RVAD During Durable LVAD Implant: Indications and Management Yoshifumi Naka, MD, PhD Columbia University Medical Center New York, NY Disclosure Abbott/St. Jude Med./Thoratec Consultant
More informationEpidemiology of Heart Failure in Adults
Cardiac Critical Care : Focused on IABP & PCPS Epidemiology of Heart Failure in Adults Prevalence Incidence Mortality 2004 Hospital Cost 2007 2004 Age 20+ (New Cases) All Ages Discharges Age 35+ 2004 All
More informationSurgery for Congenital Heart Disease. Improved early outcome for end-stage dilated cardiomyopathy in children
Improved early outcome for end-stage dilated cardiomyopathy in children Anne-Marie McMahon, MRCPCH Carin van Doorn, FRCS (C/Th) Michael Burch, FRCP Pauline Whitmore, RSCN Sophie Neligan, RSCN Philip Rees,
More information